BRAF and colorectal carcinoma: Current clinical testing of CRC includes characterization of the microsatellite status, which is considered for selection of chemotherapy regimens and for inclusion in clinical trials, along with mutations in oncogenic driver genes (BRAF, KRAS, etc.), but alterations in DNA DSB repair genes are not investigated.